<p>Unicycive Therapeutics, Inc.（納斯達克代碼：UNCY - 免費報告）- HC Wainwright 的股票研究分析師在 5 月 27 日（星期二）發佈的研究報告中發佈了 Unicycive Therapeutics 2026 年第四季度每股收益（EPS）預期。HC Wainwright 的分析師 S. Ramakanth 預計該公司本季度每股收益為 0.47 美元。HC Wainwright 對該股票給予了 “買入” 評級，目標價為 9.00 美元。市場普遍預計 Unicycive Therapeutics 當前全年的每股收益為（0.23）美元。</p>
<p>獲取 <strong>Unicycive Therapeutics</strong> 的提醒：</p>
<p>另外，Guggenheim 在 4 月 21 日（星期一）的一份報告中開始覆蓋 Unicycive Therapeutics 的股票。他們對該股票給予了 “買入” 評級，目標價為 6.00 美元。</p>
<p><strong>查看我們最新的 UNCY 股票報告</strong></p>
<h2>Unicycive Therapeutics 股票表現</h2>
<p>納斯達克 UNCY 的股票在星期三開盤價為 0.59 美元。Unicycive Therapeutics 的 52 周低點為 0.20 美元，52 周高點為 0.96 美元。該股票的市值為 7130 萬美元，市盈率為 -0.61，貝塔值為 2.14。該股票的 50 日移動平均線為 0.59 美元，200 日移動平均線為 0.61 美元。</p>
<p>Unicycive Therapeutics（納斯達克代碼：UNCY - 獲取免費報告）最近於 5 月 14 日（星期三）發佈了季度財報。該公司報告本季度每股收益為（0.05）美元，超出分析師普遍預期的（0.14）美元，超出幅度為 0.09 美元。</p>
<h2>Unicycive Therapeutics 的機構交易</h2>
<p>一些對沖基金最近對該股票的持倉進行了調整。Northern Trust Corp 在第四季度將其在 Unicycive Therapeutics 的股份增加了 142.4%。Northern Trust Corp 目前擁有 58,181 股該公司的股票，價值 46,000 美元，此前在上個季度增持了 34,183 股。XTX Topco Ltd 在第四季度將其在 Unicycive Therapeutics 的持股增加了 142.2%。XTX Topco Ltd 目前擁有 171,463 股該公司的股票，價值 136,000 美元，此前在上個季度增持了 100,679 股。Geode Capital Management LLC 在第四季度將其在 Unicycive Therapeutics 的持倉增加了 30.3%。Geode Capital Management LLC 目前擁有 524,487 股該公司的股票，價值 417,000 美元，此前在上個季度增持了 122,089 股。Acuta Capital Partners LLC 在第四季度將其在 Unicycive Therapeutics 的持股增加了 16.4%。Acuta Capital Partners LLC 目前擁有 2,303,000 股該公司的股票，價值 1,829,000 美元，此前在上個季度增持了 323,801 股。最後，Vivo Capital LLC 在第一季度將其在 Unicycive Therapeutics 的持倉增加了 14.0%。Vivo Capital LLC 目前擁有 11,370,152 股該公司的股票，價值 6,537,000 美元，此前在上個季度增持了 1,400,000 股。40.42% 的股票由機構投資者持有。</p>
<h2>Unicycive Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Unicycive Therapeutics, Inc. 是一家生物技術公司，專注於在美國開發治療腎臟疾病的新療法。該公司正在開發 Renazorb 用於治療接受透析的慢性腎病患者的高磷血癥；以及 UNI 494，目前正在進行 I 期臨牀試驗以治療急性腎損傷。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Unicycive Therapeutics</li>
<li>如何選擇評級最高的股票</li>
<li>Wix 可能在夏季上漲 50% 的 3 個理由</li>
<li>3 只雜貨股可以幫助應對通貨膨脹</li>
<li>Advance Auto Parts：收益是否緩解了關税擔憂？</li>
<li>Russell 2000 指數，投資者如何利用它進行盈利交易</li>
<li>3 只交易價格低於 52 周高點 50% 的被打壓股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VU5DWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VU5DWQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Unicycive Therapeutics 嗎？</h2>
<p>在考慮 Unicycive Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Unicycive Therapeutics 並不在名單上。</p>
<p>雖然 Unicycive Therapeutics 目前在分析師中獲得了強烈買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

UNCY

<p>HC Wainwright 分析師已發佈 Unicycive Therapeutics (NASDAQ: UNCY) 2026 年第四季度的收益預估，預計每股收益為 $0.47。該公司維持 “買入” 評級，目標價為 $9.00。目前，全年收益的共識預估為每股 ($0.23)。Unicycive 的股票開盤價為 $0.59，52 周範圍為 $0.20 至 $0.96。該公司專注於開發腎臟疾病的治療方案，包括 Renazorb 和 UNI 494</p>

<p>Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at HC Wainwright issued their Q4 2026 earnings per share (EPS) estimates for Unicycive Therapeutics in a research note issued on Tuesday, May 27th. HC Wainwright analyst S. Ramakanth expects that the company will earn $0.47 per share for the quarter. HC Wainwright has a &#34;Buy&#34; rating and a $9.00 price target on the stock. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share.</p>
<div class="lb-trans"><p>Unicycive Therapeutics, Inc.（納斯達克代碼：UNCY - 免費報告）- HC Wainwright 的股票研究分析師在 5 月 27 日（星期二）發佈的研究報告中發佈了 Unicycive Therapeutics 2026 年第四季度每股收益（EPS）預期。HC Wainwright 的分析師 S. Ramakanth 預計該公司本季度每股收益為 0.47 美元。HC Wainwright 對該股票給予了 “買入” 評級，目標價為 9.00 美元。市場普遍預計 Unicycive Therapeutics 當前全年的每股收益為（0.23）美元。</p>
</div><p>Get <strong>Unicycive Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Unicycive Therapeutics</strong> 的提醒：</p>
</div><p>Separately, Guggenheim assumed coverage on shares of Unicycive Therapeutics in a report on Monday, April 21st. They issued a &#34;buy&#34; rating and a $6.00 price target on the stock.</p>
<div class="lb-trans"><p>另外，Guggenheim 在 4 月 21 日（星期一）的一份報告中開始覆蓋 Unicycive Therapeutics 的股票。他們對該股票給予了 “買入” 評級，目標價為 6.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on UNCY</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 UNCY 股票報告</strong></p>
</div><h2>Unicycive Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Unicycive Therapeutics 股票表現</h2>
</div><p>Shares of NASDAQ UNCY opened at $0.59 on Wednesday. Unicycive Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $0.96. The stock has a market cap of $71.30 million, a PE ratio of -0.61 and a beta of 2.14. The stock has a fifty day moving average of $0.59 and a 200-day moving average of $0.61.</p>
<div class="lb-trans"><p>納斯達克 UNCY 的股票在星期三開盤價為 0.59 美元。Unicycive Therapeutics 的 52 周低點為 0.20 美元，52 周高點為 0.96 美元。該股票的市值為 7130 萬美元，市盈率為 -0.61，貝塔值為 2.14。該股票的 50 日移動平均線為 0.59 美元，200 日移動平均線為 0.61 美元。</p>
</div><p>Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.09.</p>
<div class="lb-trans"><p>Unicycive Therapeutics（納斯達克代碼：UNCY - 獲取免費報告）最近於 5 月 14 日（星期三）發佈了季度財報。該公司報告本季度每股收益為（0.05）美元，超出分析師普遍預期的（0.14）美元，超出幅度為 0.09 美元。</p>
</div><h2>Institutional Trading of Unicycive Therapeutics</h2>
<div class="lb-trans"><h2>Unicycive Therapeutics 的機構交易</h2>
</div><p>A number of hedge funds have recently made changes to their positions in the stock. Northern Trust Corp increased its stake in Unicycive Therapeutics by 142.4% in the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock valued at $46,000 after acquiring an additional 34,183 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of Unicycive Therapeutics by 142.2% in the 4th quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock worth $136,000 after purchasing an additional 100,679 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Unicycive Therapeutics by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock valued at $417,000 after purchasing an additional 122,089 shares during the last quarter. Acuta Capital Partners LLC raised its holdings in shares of Unicycive Therapeutics by 16.4% during the 4th quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock valued at $1,829,000 after buying an additional 323,801 shares in the last quarter. Finally, Vivo Capital LLC lifted its position in Unicycive Therapeutics by 14.0% in the 1st quarter. Vivo Capital LLC now owns 11,370,152 shares of the company's stock worth $6,537,000 after buying an additional 1,400,000 shares during the last quarter. 40.42% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些對沖基金最近對該股票的持倉進行了調整。Northern Trust Corp 在第四季度將其在 Unicycive Therapeutics 的股份增加了 142.4%。Northern Trust Corp 目前擁有 58,181 股該公司的股票，價值 46,000 美元，此前在上個季度增持了 34,183 股。XTX Topco Ltd 在第四季度將其在 Unicycive Therapeutics 的持股增加了 142.2%。XTX Topco Ltd 目前擁有 171,463 股該公司的股票，價值 136,000 美元，此前在上個季度增持了 100,679 股。Geode Capital Management LLC 在第四季度將其在 Unicycive Therapeutics 的持倉增加了 30.3%。Geode Capital Management LLC 目前擁有 524,487 股該公司的股票，價值 417,000 美元，此前在上個季度增持了 122,089 股。Acuta Capital Partners LLC 在第四季度將其在 Unicycive Therapeutics 的持股增加了 16.4%。Acuta Capital Partners LLC 目前擁有 2,303,000 股該公司的股票，價值 1,829,000 美元，此前在上個季度增持了 323,801 股。最後，Vivo Capital LLC 在第一季度將其在 Unicycive Therapeutics 的持倉增加了 14.0%。Vivo Capital LLC 目前擁有 11,370,152 股該公司的股票，價值 6,537,000 美元，此前在上個季度增持了 1,400,000 股。40.42% 的股票由機構投資者持有。</p>
</div><h2>Unicycive Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Unicycive Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.</p>
<div class="lb-trans"><p>Unicycive Therapeutics, Inc. 是一家生物技術公司，專注於在美國開發治療腎臟疾病的新療法。該公司正在開發 Renazorb 用於治療接受透析的慢性腎病患者的高磷血癥；以及 UNI 494，目前正在進行 I 期臨牀試驗以治療急性腎損傷。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Unicycive Therapeutics</li>
<li>How to Choose Top Rated Stocks</li>
<li>3 Reasons Wix Could Rally 50% Into the Summer</li>
<li>3 Grocery Stocks That Can Help Take a Bite Out of Inflation</li>
<li>Advance Auto Parts: Did Earnings Defuse Tariff Concerns?</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Unicycive Therapeutics</li>
<li>如何選擇評級最高的股票</li>
<li>Wix 可能在夏季上漲 50% 的 3 個理由</li>
<li>3 只雜貨股可以幫助應對通貨膨脹</li>
<li>Advance Auto Parts：收益是否緩解了關税擔憂？</li>
<li>Russell 2000 指數，投資者如何利用它進行盈利交易</li>
<li>3 只交易價格低於 52 周高點 50% 的被打壓股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VU5DWQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=UNCY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Unicycive Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Unicycive Therapeutics 嗎？</h2>
</div><p>Before you consider Unicycive Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Unicycive Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Unicycive Therapeutics 並不在名單上。</p>
</div><p>While Unicycive Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Unicycive Therapeutics 目前在分析師中獲得了強烈買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HC Wainwright 發佈了對 Unicycive Therapeutics 第四季度收益的預估